Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients

Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bortezomib / administration & dosage*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Mutation*
  • Receptors, CXCR4 / genetics*
  • Waldenstrom Macroglobulinemia* / drug therapy
  • Waldenstrom Macroglobulinemia* / genetics
  • Waldenstrom Macroglobulinemia* / mortality

Substances

  • CXCR4 protein, human
  • Receptors, CXCR4
  • Bortezomib